Novo Holdings, the main owner of Novo Nordisk A/S (NYSE:NVO), plans to use dividends from NVO's successful weightloss drugs Ozempic and Wegovy for strategic investments, particularly in Asia. Despite challenges such as interest rates and geopolitics, Novo Holdings is set for an active dealmaking role, with its annual payout expected to nearly double. NVO's share price saw a slight decrease in premarket trading.